MissionIR Articles
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Q2 Virtual Investor Summit
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO John Climaco will present…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) on Track to Begin Potentially Pivotal Phase 2 GBM Trial This Quarter for Berubicin
During Phase 1 trials, Berubicin showed 44% of patients experienced a clinical benefit of stable disease or better, one being cancer-free after 14 years, and two patients reporting significant tumor reduction (up to 80%) Additional…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Start Potentially Pivotal Berubicin Trial
CNS Pharmaceuticals (NASDAQ: CNSP) is working to determine the efficacy of its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive type of brain cancer for which there is currently no…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than Daunorubicin
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial
CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat…
-
Patients with Incurable Brain Cancers Find New Hope in University Study, Upcoming CNS Pharmaceuticals (NASDAQ: CNSP) Clinical Trial
Glioblastoma Multiforme (often known simply as GBM) is a fatal, incurable class of brain cancers that usually leaves patients only about 15 months to live once they are diagnosed A recent study by the Washington…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) New Investor Presentation Shows Value-Added Milestones for Berubicin in 2021
GBM is diagnosed in more than 13,000 people each year in the US, with only a 12–18-month life expectancy Potentially pivotal Phase 2 trial of Berubicin is scheduled to commence around the end of Q1…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Continues to Advance Toward Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that the Wroclaw, Poland-based Lower Silesian Medical Chamber Ethics Committee gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), the company’s sublicensee in Europe and Asia for its lead drug…
-
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Begin Enrolling Brain Cancer Drug Trial Participants
Brain cancer drug developer CNS Pharmaceuticals is finalizing preparations to begin March enrollment of patients in its potentially pivotal Phase 2 trial evaluating its promising lead candidate, Berubicin, for the overall survival improvement of glioblastoma…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in First-Ever Emerging Growth Virtual Conference
CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco will be presenting at the inaugural Emerging Growth Virtual Conference. Scheduled for March 17–18, the virtual conference is presented by M Vest LLC and Maxim Group LLC. The…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leverages ‘Absolute Powerhouse Compound’ as IND Status Paves Way for Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco, in a recent podcast, showed his excitement at news that the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status. The IND designation…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) Get the Green Light for Clinical Trials’ Protocols from Ethics Panels
CNS Pharmaceuticals holds the exclusive worldwide license to the Berubicin chemical compound Berubicin is CNSP’s lead, novel anthracycline candidate for the treatment of glioblastoma multiforme (“GBM”) that was the subject of a previously conducted Phase…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Upcoming H.C. Wainwright Global Life Sciences Conference
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the company’s CEO, John Climaco, will…
-
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic About Upcoming Berubicin Trials After IND Approval
Berubicin is CNS Pharmaceuticals’ lead product candidate for treatment of Glioblastoma Multiforme, and has the potential to be the first anthracycline to cross the blood-brain barrier based on limited results from a Phase 1 trial…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Progress Toward Upcoming Berubicin Trial
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today confirmed that the clinical program for Berubicin is…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Agreement for Upcoming Berubicin Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, have entered into…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Transformation as Berubicin Becomes Subject of Active Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. The company’s pipeline includes Berubicin for the treatment…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Key Milestone, Progress Toward Collaborative Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that…
-
CNS Pharmaceuticals (NASDAQ: CNSP) Celebrates IND Status, Prepares to Launch Brain Cancer Drug Trials
Brain cancer drug developer CNS Pharmaceuticals is celebrating recent news that the U.S. Food and Drug Administration (“FDA”) granted investigational new drug (“IND”) status to CNS Pharmaceuticals’ leading candidate for fighting glioblastomas Glioblastomas are a…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) on the Verge of Changing History with Berubicin
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, has set sights on an encouraging future for glioblastoma…
Search Articles
Latest Articles
- A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Advancing Retail Innovation Through AI-Powered Smart-Cart Technology
- Forward Industries Inc. (NASDAQ: FWDI) Positive Update for Shareholders After Debuting the Company’s Solana Treasury Strategy
- Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures Funding to Strengthen North American Supply Chain
- MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast